Tarsus Pharmaceuticals, Inc. (TARS) Ownership
TARS ownership summary
as of October 18, 2026- Institutions
- 99.3% of shares outstanding
- Insiders
- 2.69% of shares outstanding
- Shares outstanding
- 46.8M
- Float
- 32.7M shares available to trade
- Short interest
- 13.37% 6.1M shares short
- Days to cover
- 7.31 short interest down 0.9% vs prior month
- Institutions 99.26%
- Insiders 2.69%
TARS top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | BlackRock Inc | 8.24% | 3.9M | $262.5M | +303,525 (+8.5%) | June 30, 2026 |
| 2 | Deep Track Capital, LP | 7.84% | 3.7M | $249.6M | +66,768 (+1.9%) | June 30, 2026 |
| 3 | RTW INVESTMENTS, LLC | 7.17% | 3.4M | $228.5M | +11,034 (+0.3%) | June 30, 2026 |
| 4 | Jupiter Topco LLC | 6.00% | 2.8M | $191.2M | +2.8M (0.0%) | June 30, 2026 |
| 5 | Paradigm Biocapital Advisors LP | 5.93% | 2.8M | $188.9M | +213,495 (+8.3%) | June 30, 2026 |
| 6 | HHG PLC | 4.79% | 2.2M | $152.5M | +310,638 (+16.1%) | March 31, 2026 |
| 7 | Assenagon Asset Management SA | 4.05% | 1.9M | $129.0M | +614,796 (+48.0%) | June 30, 2026 |
| 8 | Morgan Stanley - Brokerage Accounts | 3.90% | 1.8M | $124.4M | −117,190 (−6.0%) | June 30, 2026 |
| 9 | Vanguard Capital Management, LLC | 3.83% | 1.8M | $122.1M | +32,523 (+1.8%) | June 30, 2026 |
| 10 | Jennison Associates LLC | 3.56% | 1.7M | $113.2M | −48,469 (−2.8%) | June 30, 2026 |
| 11 | TANG CAPITAL MANAGEMENT LLC | 3.35% | 1.6M | $106.8M | +379,642 (+31.9%) | June 30, 2026 |
| 12 | Millennium Management LLC | 3.05% | 1.4M | $97.1M | +862,545 (+152.8%) | June 30, 2026 |
| 13 | Bank of America Corp | 2.55% | 1.2M | $81.2M | −1,195 (−0.1%) | June 30, 2026 |
| 14 | Geode Capital Management, LLC | 2.36% | 1.1M | $75.3M | −15,402 (−1.4%) | June 30, 2026 |
| 15 | State Street Corp | 2.29% | 1.1M | $73.0M | +94,739 (+9.7%) | June 30, 2026 |
| 16 | Vestal Point Capital LP | 2.24% | 1.1M | $71.5M | +850,000 (+425.0%) | June 30, 2026 |
| 17 | Amvescap Plc. | 1.68% | 786K | $53.5M | +43,311 (+5.8%) | June 30, 2026 |
| 18 | The Goldman Sachs Group Inc | 1.59% | 743K | $50.6M | +303,067 (+68.9%) | June 30, 2026 |
| 19 | Frazier Life Sciences Management, L.P. | 1.56% | 729K | $49.6M | — | June 30, 2026 |
| 20 | D. E. Shaw & Co LP | 1.52% | 711K | $48.4M | −80,587 (−10.2%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 14 holders added 6.9M shares and 5 cut 263K.
TARS top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Vanguard MStar Total Stk Mkt Idx Invest | 2.78% | 1.3M | $88.5M | −2,318 (−0.2%) | August 31, 2026 |
| 2 | iShares Russell 2000 ETF | 2.32% | 1.1M | $73.8M | −12,480 (−1.1%) | September 30, 2026 |
| 3 | Fidelity Small Cap Index | 0.98% | 458K | $31.2M | +4,227 (+0.9%) | July 31, 2026 |
| 4 | Janus Henderson Global Life Sciences D | 0.88% | 409K | $27.9M | +49,904 (+13.9%) | August 31, 2026 |
| 5 | iShares Russell 2000 Growth ETF | 0.84% | 392K | $26.7M | −496 (−0.1%) | September 30, 2026 |
| 6 | Janus Henderson Glb Life Scn I2 USD | 0.84% | 391K | $26.6M | +44,330 (+12.8%) | August 31, 2026 |
| 7 | PGIM Jennison Small Company A | 0.80% | 372K | $25.3M | −36,246 (−8.9%) | September 30, 2026 |
| 8 | Fidelity Select Health Care | 0.77% | 360K | $24.5M | +360,000 (0.0%) | August 31, 2026 |
| 9 | Janus Global Life Science AUSD | 0.74% | 347K | $23.6M | +71,386 (+25.9%) | June 30, 2026 |
| 10 | Janus Henderson Hrzn Biotec E2 USD | 0.69% | 323K | $22.0M | +28,716 (+9.8%) | June 30, 2026 |
| 11 | iShares Biotechnology ETF | 0.69% | 322K | $21.9M | −2,440 (−0.8%) | September 30, 2026 |
| 12 | Janus Henderson Triton D | 0.61% | 284K | $19.3M | — | August 31, 2026 |
| 13 | Invesco Pharmaceuticals ETF | 0.53% | 250K | $17.0M | +554 (+0.2%) | September 30, 2026 |
| 14 | Loomis Sayles Small Cap Growth Instl | 0.53% | 247K | $16.8M | +16,741 (+7.3%) | August 31, 2026 |
| 15 | Vanguard Russell 2000 ETF | 0.52% | 243K | $16.6M | +2,730 (+1.1%) | September 30, 2026 |
| 16 | ClearBridge Small Cap Growth A | 0.51% | 238K | $16.2M | −71,400 (−23.1%) | September 30, 2026 |
| 17 | Fidelity Growth Company Fund | 0.49% | 229K | $15.6M | — | August 31, 2026 |
| 18 | MEDICAL BioHealth EUR Acc | 0.47% | 219K | $14.9M | −181,975 (−45.4%) | August 31, 2026 |
| 19 | PGIM Jennison Health Sciences Z | 0.47% | 219K | $14.9M | −29,445 (−11.9%) | September 30, 2026 |
| 20 | abrdn Healthcare Investors | 0.45% | 212K | $14.4M | — | September 30, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
TARS insider transactions
latest 20| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-19 | Bryan Wahl | Sell | $67.00 | 4,231 | $283,477 |
| 2026-03-19 | Dianne C Whitfield | Sell | $67.00 | 4,174 | $279,658 |
| 2026-03-19 | Elizabeth Yeu Lin | Sell | $67.00 | 390 | $26,130 |
| 2026-03-19 | Jeffrey S Farrow | Sell | $67.00 | 2,186 | $146,462 |
| 2026-03-19 | Bobak R Azamian | Sell | $67.00 | 11,964 | $801,588 |
| 2026-03-18 | Bobak R Azamian | Sell | $68.71 | 11,667 | $801,640 |
| 2026-03-18 | Bryan Wahl | Sell | $68.71 | 4,125 | $283,429 |
| 2026-03-18 | Dianne C Whitfield | Sell | $68.71 | 4,071 | $279,718 |
| 2026-03-18 | Elizabeth Yeu Lin | Sell | $68.71 | 379 | $26,041 |
| 2026-03-18 | Jeffrey S Farrow | Sell | $68.71 | 2,133 | $146,558 |
| 2026-03-17 | Bobak R Azamian | Sell | $69.42 | 10,972 | $761,676 |
| 2026-03-17 | Jeffrey S Farrow | Sell | $69.42 | 2,111 | $146,546 |
| 2026-03-17 | Elizabeth Yeu Lin | Sell | $69.42 | 375 | $26,032 |
| 2026-03-17 | Dianne C Whitfield | Sell | $69.42 | 4,029 | $279,693 |
| 2026-03-17 | Bryan Wahl | Sell | $69.42 | 4,084 | $283,511 |
| 2026-03-16 | William J Phd Link | Sell | $68.79 | 12,500 | $859,875 |
| 2025-12-24 | Bobak R Azamian | Sell | $82.51 | 6,000 | $495,060 |
| 2025-12-16 | Dianne C Whitfield | Sell | $80.10 | 7,397 | $592,500 |
| 2025-09-24 | Bobak R Azamian | Sell | $55.37 | 6,000 | $332,220 |
| 2025-09-08 | William J Phd Link | Sell | $57.00 | 27,116 | $1.5M |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
TARS shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns TARS
Institutional investors own 99.3% of Tarsus Pharmaceuticals's shares and insiders 2.69%. The largest holder is BlackRock Inc with 8.24% of the shares (3.9M), as of June 30, 2026. Among the top 20 institutions, 14 added shares and 5 reduced their stake in the latest filings. Short interest is 13.37% of the float, or 7.31 days of average trading volume. The share count rose 898.4% since 2017.
Related: TARS analyst forecast, TARS key metrics. See the TARS stock overview for the latest quote and news.
TARS ownership FAQ
Who owns the most Tarsus Pharmaceuticals stock?
The largest shareholders of Tarsus Pharmaceuticals are BlackRock Inc (8.24%), Deep Track Capital, LP (7.84%), RTW INVESTMENTS, LLC (7.17%), Jupiter Topco LLC (6.00%), Paradigm Biocapital Advisors LP (5.93%).
What percentage of Tarsus Pharmaceuticals is owned by institutions?
Institutions hold 99.3% of Tarsus Pharmaceuticals's shares outstanding; insiders hold 2.69%.
Which funds own Tarsus Pharmaceuticals?
The largest fund holders of Tarsus Pharmaceuticals are Vanguard MStar Total Stk Mkt Idx Invest (2.78%), iShares Russell 2000 ETF (2.32%), Fidelity Small Cap Index (0.98%), Janus Henderson Global Life Sciences D (0.88%), iShares Russell 2000 Growth ETF (0.84%).
What is Tarsus Pharmaceuticals's short interest?
6.1M shares of Tarsus Pharmaceuticals were sold short, 13.37% of the float; at the average daily volume it would take 7.31 days to cover.
Are insiders buying or selling Tarsus Pharmaceuticals?
Of the latest 20 reported insider transactions in Tarsus Pharmaceuticals (since September 8, 2025), 0 were purchases and 20 were sales.
How many shares of Tarsus Pharmaceuticals are outstanding?
Tarsus Pharmaceuticals has 46.8M shares outstanding, of which 32.7M are in the public float.